Mesoporous Silica Market Size, Share & Trends Analysis Report By Product (M41S Series, SBA Series, Others), By Application (Catalysts, Drug Delivery, Environmental Protection, Others), By Region, And Segment Forecasts, 2023 - 2030

Mesoporous Silica Market Size, Share & Trends Analysis Report By Product (M41S Series, SBA Series, Others), By Application (Catalysts, Drug Delivery, Environmental Protection, Others), By Region, And Segment Forecasts, 2023 - 2030

Mesoporous Silica Market Growth & Trends

The global mesoporous silica market size is expected to reach USD 388.7 million by 2030, registering a CAGR of 10.4% from 2023 to 2030, according to a new report by Grand View Research, Inc. Rising product penetration in the pharmaceutical industry is expected to be a major driver for the market growth over the forecast period. Thermal stability, favorable chemical properties, and biocompatibility attributes of the mesoporous silica are anticipated to drive its demand in the pharmaceutical industry. The value chain of the market consists of raw material suppliers, manufacturers, research laboratories, distributors, and end-users.

The product is anticipated to be in the research stage and the market is characterized by a limited number of players engaged in the production and supply. The industry exhibits a moderate presence of established players controlling a significant market share. The product demand is anticipated to be the highest in biomedical applications, which has prompted companies to focus more on research activities for the medical sector. Ongoing research and continuous development are expected to offer numerous growth opportunities in the medical industry.

Mesoporous Silica Market Report Highlights

• The SBA series segment accounted for the largest revenue share of 44.0% in 2022 and is expected to further expand at the fastest CAGR of 11.5% during the forecast period on account of its properties of enhanced thermochemical stability desired for various pharmaceutical applications
• The drug delivery segment held the largest revenue share of 42.9% in 2022 owing to its high surface area, biocompatibility, and ease of surface modification desired as an active drug ingredient in several treatments including cancer
• Asia Pacific is expected to expand at the fastest CAGR of 11.5% during the forecast period, in terms of revenue, owing to the rapid growth of the pharmaceutical industry and increasing expenditure on wastewater treatment
• The major manufacturers, such as Merck KGaA and Taiyo International, emphasize on the implementation of new technologies and R&D activities to have a competitive advantage and to serve various application requirements

Please note The report will be delivered in 4-6 business days upon order notification.